Astria Therapeutics, Inc. (ATXS)
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
Address
22 BOSTON WHARF ROAD
BOSTON, MA 02210
Founded
2008
Number of Employees
59
Website
http://www.astriatx.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)